Literature DB >> 21148790

Trimethylangelicin reduces IL-8 transcription and potentiates CFTR function.

Anna Tamanini1, Monica Borgatti, Alessia Finotti, Laura Piccagli, Valentino Bezzerri, Maria Favia, Lorenzo Guerra, Ilaria Lampronti, Nicoletta Bianchi, Francesco Dall'Acqua, Daniela Vedaldi, Alessia Salvador, Enrica Fabbri, Irene Mancini, Elena Nicolis, Valeria Casavola, Giulio Cabrini, Roberto Gambari.   

Abstract

Chronic inflammatory response in the airway tract of patients affected by cystic fibrosis is characterized by an excessive recruitment of neutrophils to the bronchial lumina, driven by the chemokine interleukin (IL)-8. We previously found that 5-methoxypsoralen reduces Pseudomonas aeruginosa-dependent IL-8 transcription in bronchial epithelial cell lines, with an IC(50) of 10 μM (Nicolis E, Lampronti I, Dechecchi MC, Borgatti M, Tamanini A, Bezzerri V, Bianchi N, Mazzon M, Mancini I, Giri MG, Rizzotti P, Gambari R, Cabrini G. Int Immunopharmacol 9: 1411-1422, 2009). Here, we extended the investigation to analogs of 5-methoxypsoralen, and we found that the most potent effect is obtained with 4,6,4'-trimethylangelicin (TMA), which inhibits P. aeruginosa-dependent IL-8 transcription at nanomolar concentration in IB3-1, CuFi-1, CFBE41o-, and Calu-3 bronchial epithelial cell lines. Analysis of phosphoproteins involved in proinflammatory transmembrane signaling evidenced that TMA reduces the phosphorylation of ribosomal S6 kinase-1 and AKT2/3, which we found indeed involved in P. aeruginosa-dependent activation of IL-8 gene transcription by testing the effect of pharmacological inhibitors. In addition, we found a docking site of TMA into NF-κB by in silico analysis, whereas inhibition of the NF-κB/DNA interactions in vitro by EMSA was observed at high concentrations (10 mM TMA). To further understand whether NF-κB pathway should be considered a target of TMA, chromatin immunoprecipitation was performed, and we observed that TMA (100 nM) preincubated in whole living cells reduced the interaction of NF-κB with the promoter of IL-8 gene. These results suggest that TMA could inhibit IL-8 gene transcription mainly by intervening on driving the recruitment of activated transcription factors on IL-8 gene promoter, as demonstrated here for NF-κB. Although the complete understanding of the mechanism of action of TMA deserves further investigation, an activity of TMA on phosphorylating pathways was already demonstrated by our study. Finally, since psoralens have been shown to potentiate cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride transport, TMA was tested and found to potentiate CFTR-dependent chloride efflux. In conclusion, TMA is a dual-acting compound reducing excessive IL-8 expression and potentiating CFTR function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148790     DOI: 10.1152/ajplung.00129.2010

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  17 in total

1.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

Review 2.  Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator.

Authors:  James F Collawn; Lianwu Fu; Rafal Bartoszewski; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-25       Impact factor: 5.464

Review 3.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 4.  CFTR and lung homeostasis.

Authors:  James F Collawn; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-07       Impact factor: 5.464

5.  Pseudomonas aeruginosa reduces the expression of CFTR via post-translational modification of NHERF1.

Authors:  Rosa Rubino; Valentino Bezzerri; Maria Favia; Marcella Facchini; Maela Tebon; Anurag Kumar Singh; Brigitte Riederer; Ursula Seidler; Antonio Iannucci; Alessandra Bragonzi; Giulio Cabrini; Stephan J Reshkin; Anna Tamanini
Journal:  Pflugers Arch       Date:  2014-03-05       Impact factor: 3.657

Review 6.  Molecular basis of cystic fibrosis: from bench to bedside.

Authors:  Maria Cristina Dechecchi; Anna Tamanini; Giulio Cabrini
Journal:  Ann Transl Med       Date:  2018-09

7.  Bergamot (Citrus bergamia Risso) fruit extracts and identified components alter expression of interleukin 8 gene in cystic fibrosis bronchial epithelial cell lines.

Authors:  Monica Borgatti; Irene Mancini; Nicoletta Bianchi; Alessandra Guerrini; Ilaria Lampronti; Damiano Rossi; Gianni Sacchetti; Roberto Gambari
Journal:  BMC Biochem       Date:  2011-04-15       Impact factor: 4.059

8.  Induction of erythroid differentiation and increased globin mRNA production with furocoumarins and their photoproducts.

Authors:  Alessia Salvador; Eleonora Brognara; Daniela Vedaldi; Ignazio Castagliuolo; Paola Brun; Cristina Zuccato; Ilaria Lampronti; Roberto Gambari
Journal:  J Photochem Photobiol B       Date:  2013-02-27       Impact factor: 6.252

9.  Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.

Authors:  Emilie Lyne Saussereau; Delphine Roussel; Siradiou Diallo; Laurent Debarbieux; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

10.  Modulation of the expression of the proinflammatory IL-8 gene in cystic fibrosis cells by extracts deriving from olive mill waste water.

Authors:  Ilaria Lampronti; Monica Borgatti; Silvia Vertuani; Stefano Manfredini; Roberto Gambari
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-07       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.